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Abstract 
 
Matrix protein mutant strains of VSV, such as rM51R-M virus, are currently being 
investigated as oncolytic agents due to their ability to target and kill cancer cells while also 
stimulating innate immunity. We seek to examine the ability of rM51R-M virus to modulate 
tumor promoting M2 macrophages as a means to inhibit the progression of cancer. In the 
tumor microenvironment, M2 macrophage activity has a suppressive effect on the immune 
system, which can lead to tolerance of tumor cells. M1 macrophages, in contrast, stimulate an 
immune response and reduce tumor cell viability. Our lab has previously shown that  
rM51R-M virus re-educates M2 macrophages to an M1-like phenotype, but the mechanism 
by which it does so remains unknown. In THP-1 polarized M2 macrophages, we have 
observed increased levels of IFNα, total STAT1, and p-STAT1 upon infection with  
rM5IR-M virus. We hypothesize that the ability of rM51R-M virus to stimulate the type I 
IFN antiviral pathway in M2 macrophages may coerce them to an M1-like phenotype. To test 
this hypothesis, we seek to examine the effects of the p-STAT1 inhibitor fludarabine on 
macrophage polarization by rM51R-M virus. M2 macrophages were pretreated with different 
concentrations of fludarabine (50, 100, or 150 µM), infected with rM51R-M virus (MOI 1 or 
10 pfu/cell) for 24 hours, and subjected to immunoblot analysis for total and phosphorylated 
STAT1. Results indicated that when cells were infected with rM51R-M virus at an MOI of 1, 
STAT1 phosphorylation was reduced to between 23% (50 µM fludarabine) and 16 % (100 
and 150 µM fludarabine) of control levels. Similar results were obtained when cells were 
infected at an MOI of 10. These results confirm that fludarabine is capable of inhibiting the 
accumulation of p-STAT1. Therefore, this reagent can be used to reduce type I IFN signaling 
in order to determine the extent to which this pathway modulates macrophage identity during 
rM51R-M infection. Such mechanistic insights will be important in understanding the 
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BCA: bicinchoninic acid 
BHK: baby hamster kidney 
BSA: bovine serum albumin 
CAR-T cells: chimeric antigen receptor T-cells 
CCL: chemokine (C-C motif) ligand 
CD: cluster of differentiation (often used as an identity marker) 
CSF1: colony stimulating factor 1 
DMSO: dimethyl sulfoxide 
EGF: epidermal growth factor 
HLA-DR: human leukocyte antigen-DR isotype 
IFNI: interferon type I (includes interferon alpha, beta, and others) 
IFNAR: human type I interferon receptor 
IL: interleukin 
iNOS: inducible isoform of nitric oxide synthase 
IRF: interferon regulatory factor 
JAK1: Janus kinase 1 
M1: inflammatory macrophage 
M2: immunosuppressive macrophage 
MDA-MB-231: human triple-negative breast cancer cell line 
MMP: matrix metalloproteinase 
MOI: multiplicity of (viral) infection 
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MyD88: adaptor protein in the TLR signaling pathway leading to NFκB activation 
NCI: National Cancer Institute  
NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells 
Nos2: nitric oxide synthase 2 
PBS: phosphate buffered saline 
PD-L1: programmed death-ligand 1 
pfu: plaque forming units 
PMA: phorbol 12-myristate 13-acetate 
p-STAT1: phosphorylated signal transducer and activator of transcription 1 
RIPA buffer: radioimmunoprecipitation assay buffer 
rM51R-M virus: matrix protein mutant of vesicular stomatitis virus (change of methionine to 
arginine at position 51) 
SDS: sodium dodecyl sulfate 
TAM: tumor associated macrophage 
TBS-T: Tris-buffered saline containing Tween 20 
TGF-β: transforming growth factor beta 
THP-1: human monocytic leukemia cell line 
TLR: toll-like receptor 
TNF-α: tumor necrosis factor alpha 
Tris: tris(hydroxymethyl)aminomethane 
VEGF: vascular endothelial growth factor 






According to the National Cancer Institute (NCI), approximately 1 in 3 men and 
women will receive a cancer diagnosis in their lifetimes (Siegel et. al. 2019). Accordingly, 
the NCI has an annual budget exceeding $5 billion dollars. That money, along with resources 
from pharmaceutical companies and non-profits, supports a staggering infrastructure 
designed to alleviate the significant health and financial burdens caused by this disease. Yet 
despite this long-term effort that symbolically began with the National Cancer Act of 1971, 
standard-of-care treatments still rely on techniques developed decades ago, including 
surgery, radiation, and chemotherapy. These treatments often come with devastating side 
effects and are less effective at later stages of the disease when cancer cells have 
metastasized to distant regions of the body. Current research efforts seek to alleviate these 
issues with next generation cancer therapies. One proposed category of treatment is the 
recruitment of the patient’s own immune system to fight against the tumor. In this vein, our 
project seeks to modulate the functionality of an immune cell, the macrophage, through the 
use of an oncolytic virus. 
Macrophages are a component of the innate and adaptive immune systems. As blood 
monocytes with origins in the bone marrow, they specialize as they move into tissue in 
response to signaling molecules. Some macrophages are tissue-specific, such as the alveolar 
macrophages of the lungs or the microglia of the central nervous system. However, in most 
of the body’s tissues, macrophages polarize based on the needs of the immune system at the 
time of monocyte maturity.  
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Macrophages were previously classified using a binary system that separated them 
into M1 or M2 phenotypes (Locati et. al. 2020). However, additional research has shown that 
macrophages are more heterogeneous than formerly believed, with phenotypes that parallel 
the diverse signals that activate them (Xue et. al. 2014, Roussel et. al. 2017). For example, 
IL-4 and IL-10 polarize macrophages to the M2 phenotype. However, macrophages 
stimulated with only IL-4 or only IL-10 exhibited significant phenotypic differences from 
each other, suggesting that it may be beneficial to categorize them separately (Roussel et. al. 
2017). Still, the M1 and M2 distinction can be useful for defining macrophages based on 
their more general functions. M1 macrophages, for example, are pro-inflammatory and 
promote T-cell activity. These macrophages also assist in the clearance of pathogenic 
bacteria and have antitumoral properties. Human M1 macrophages express HLA-DR, iNOS, 
CD86, and p-STAT1 in higher proportion than their M2 counterparts. They also secrete 
inflammatory cytokines like IL-6, IL-12, IL-23, and TNF-α, as well as reactive oxygen and 
nitrogen species (Jayasingam et. al. 2020, Locati et. al. 2020). M2 macrophages, in contrast, 
express higher levels of CD206, CD204, CCL22, CCL17, and CD163 and secrete cytokines 
that suppress immune activity like IL-10, PD-L1, and TGF-β. They also exert tissue repair 
functions by secreting adrenomedullin and VEGF, both of which support the growth of blood 
vessels (Jayasingam et. al. 2020, Locati et. al. 2020). The immunosuppressive nature of M2 
macrophages helps diminish over-stimulation of the immune system and promotes normal 
tissue growth (Petty and Yang 2017). Ultimately it is the balance between M1 and M2 
macrophage phenotypes that allows the body to protect itself from harmful pathogens while 
also preventing and repairing damage to its own tissues. 
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Macrophage populations within the tumor microenvironment have long been 
implicated in the development of aggressive cancers. A 2017 meta-analysis of breast cancer 
patient data revealed that a high density of tumor-associated macrophages (TAMs) resulted 
in increased markers of aggressive cancer and correlated with lower overall survival (Zhao 
et. al. 2017). This is largely attributable to a high density of M2 macrophages in the tumor 
microenvironment. M2 macrophages make up such a large proportion of TAMs that the 
terms are sometimes used interchangeably. The prevalence of this subtype among TAMs is 
due to cytokines secreted by tumor cells that promote M2 polarization, such as CSF1 and 
TGF-β (Petty and Yang 2017). In the context of cancer, the M2 subtype is detrimental to the 
patient, causing the immune system to tolerate the presence of the tumor. M2 macrophages 
also directly promote cancer cell growth, angiogenesis, and metastasis. These pro-tumor 
functions occur as a result of cytokine and surface signaling on M2 macrophages, including 
but not limited to VEGF, which promotes angiogenesis, EGF, which is a pro-tumoral growth 
factor, and MMPs, a class of proteases that aid in tissue remodeling during cancer cell 
invasion and metastasis (Anfray et. al. 2019, Zhao et. al. 2017, Petty and Yang 2017). 
 Not all TAMs are pro-tumoral. The M1 subtype among TAM populations can be 
beneficial to the patient. They promote the activation of cytotoxic T-cells and generate 
reactive nitrogen and oxygen species that contribute to cancer cell death. M1 TAMs have 
shown promise for the clearance of melanoma in mouse models of the disease (Petty and 
Yang 2017). The pro-inflammatory, anti-tumor properties of M1 macrophages make them 
desirable in a patient’s tumor microenvironment. 
Modulation of macrophage identity is a promising avenue for anti-cancer therapies. 
Some common therapeutic strategies of macrophage modulation include inhibition of 
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macrophage movement to the tumor site and the conversion of M2 TAMs into M1 TAMs. 
Suppression or depletion of all TAMs (or just M2 TAMs) are also popular strategies (Tariq 
et. al. 2017). Each strategy shows promise and can employ multiple therapeutic techniques. 
For example, CAR-T cells are one possible avenue of M2 macrophage depletion. Chimeric 
antigen receptor (CAR)-T cells are modified leukocytes containing a genetically engineered 
CAR protein that identifies a selected target antigen. They are typically used to destroy 
cancer cells expressing disease-specific proteins (Sermer and Brentjens, 2019). CAR-T cells 
have also been used to target and eliminate TAMs expressing M2 markers. An ovarian 
cancer mouse model displayed slower tumor growth and increased survival when such 
macrophage depletion was coupled with tumor-targeting CAR-T cells as opposed to tumor 
targeting alone (Rodriguez-Garcia et. al. 2021). Another research group found that the 
chemotherapeutic agent hydroxychloroquine suppresses non-small cell lung cancer in part 
because it promotes the transition of M2 macrophages into an M1-like phenotype (Li et. al. 
2018). These two examples represent just a fraction of the potential routes for clinically 
relevant macrophage alteration. 
Another potential route for macrophage modulation is the use of oncolytic viruses. 
An oncolytic virus is one that can kill cancer cells with minimal damage to normal host 
tissue. These viruses can be either naturally occurring or genetically modified (Fukuhara et. 
al. 2016). My efforts have focused on vesicular stomatitis virus (VSV). VSV is a pathogen of 
livestock, such as horses and pigs, and is transmitted through an insect vector. Human 
infections are rare and mild, having mostly occurred in lab personnel working with the virus 
or in animal handlers. Multiple tissue culture cell lines are permissible to infection by wild-
type VSV, making it particularly useful in both viral research and clinical applications. VSV 
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is capable of inducing apoptosis in cancer cells through multiple, independent mechanisms 
(Bishnoi et. al. 2018). It has specifically been shown to lyse cells in hypoxic tumor 
microenvironments, and therefore may alleviate the tumor-promoting stress associated with 
increased resistance to radiation and chemotherapy. In this way, the virus may sensitize 
tumor cells to chemotherapy (Bishnoi et. al. 2018). In addition to VSV’s direct effects on 
tumor cells, the virus has shown the ability to indirectly lower tumor viability. As VSV can 
infect the tumor vasculature, the virus may lead to decreased blood flow and increased 
immune cell infiltration of the tumor (Bishnoi et. al. 2018). 
Multiple clinical trials are investigating the use of VSV mutants as cancer therapies, 
many of which are modified to express IFNβ (Table 1). The inclusion of the IFNβ gene has 
been shown to improve the safety of the virus without compromising its anti-cancer 
properties (Kurisetty et. al. 2014). Other engineered VSV strains may also increase the 
cancer-fighting activity of tumor-associated immune cells while maintaining a high level of 
patient safety. One example is rM5IR-M, a matrix protein mutant of VSV. A change from 
methionine to arginine at position 51 in the matrix protein sequence renders the virus 
incapable of inhibiting host immune gene expression (Figure 1). Typically, matrix protein-
mediated repression of host gene expression prohibits anti-viral responses in infected 
organisms. For example, most wild type VSV viruses suppress the type I IFN anti-viral 
response in the host, thus supporting continued viral infection. rM51R-M virus, however, 
upregulates this pathway, and thereby increases the immune modulatory capabilities of the 
virus, thus making rM51R-M an ideal oncolytic virus with which to enact phenotypic shifts 
in macrophage polarization (Ahmed et al. 2006). rM51R-M virus has also shown low 







Table 1. VSV variants currently in clinical trials.  











Advanced Malignant Solid Neoplasm 
Hepatocellular Carcinoma 
NCT01628640 1 
VSV-IFNβ-NIS Malignant Solid Tumor NCT02923466 1 
VSV-IFNβ-NIS Solid Tumor 
Head and Neck Squamous Cell Carcinoma 
Non Small Cell Lung Cancer 
NCT03647163 1 









Figure 1. Genomic and morphological structure of wild type VSV. Panel A shows the 
orientation of genes along the negative-stranded RNA genome of VSV. Panel B shows the 
protein localization within a single viral particle. Images are based on those from the Swiss 
Institute of Bioinformatics and Michael Dumiak. 
 
 
Previous experiments in our lab have shown that rM5IR-M virus may polarize 
macrophages towards a more inflammatory phenotype. This is indicated by the increased 
expression of the M1 markers p-STAT1, CD80, and TNF-α following infection of a M2 
THP-1 macrophage population (Polzin 2020). Additionally, in a co-culture of M2 THP-1 
macrophages and MDA-MB-231 breast cancer cells, infection with rM51R-M virus resulted 
in a significant reduction of the M2 marker IL-10 (McCanless 2019). Therefore, 
macrophages appear to be moving away from the immunosuppressive M2 subtype as a result 
of rM51R-M viral infection. 
Like many viruses, rM51R-M virus stimulates the type I interferon (IFN) pathway. 
This pathway participates in anti-viral responses as well as M1 macrophage polarization 
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(Figure 2). Viral infection stimulates the production of type I IFNs (IFNα or IFN β) in most 
cell types (Samuel 2001). When IFNα or IFN β binds to the IFNα/β receptor (IFNAR), it 
stimulates the autophosphorylation of JAK1. This triggers the phosphorylation of STAT1, 
which forms a dimer with phosphorylated STAT2. The dimer then associates with IRF9 and 
moves into the nucleus where it induces an antiviral response (Figure 2A) (Ivashkiv and 
Donlin 2014). This response includes the production of proteins that damage or prevent 
translation of viral RNA, as well as proteins targeting viral nucleocapsids. IFN signaling can 
also lead to the production of major histocompatibility antigens, which recruit cytotoxic T 
cells, and nitric oxide synthase, which can produce reactive chemical species that kill viruses 
(Samuel 2001). Transcriptional regulation by this pathway also leads to the production of 
additional IFNα/β. 
The type I IFN pathway can also take part in M1 macrophage polarization. The 
STAT1/2 dimer produced by the type I IFN pathway (typically as a result of IFNβ signaling) 
can synergize with NFκB downstream of toll-like receptor (TLR) activation. This synergy 
leads to transcriptional regulation of, for example, Nos2, a gene producing some of the 
reactive nitrogen species characteristic of M1 macrophages (Figure 2B) (Müller et. al. 2018). 
The type I IFNs that trigger M1 polarization may come from virus-infected cells. They may 
also come from previously activated macrophages or dendritic cells (another immune cell 





Figure 2. Comparison of type I IFN pathways during an antiviral response and 
during M1 macrophage polarization. Panel A shows the type I IFN pathway that 
leads to an anti-viral response. Following the binding of a type I IFN to IFNAR, 
JAK1 phosphorylates STAT1, which forms a dimer with phosphorylated STAT2. The 
dimer then associates with IRF9 and moves into the nucleus to modulate 
transcription, leading to upregulation of anti-viral proteins. Panel B shows the 
polarization of an M1 macrophage by IFNβ. The pathway is very similar to the anti-
viral response, with a phosphorylated STAT1-STAT2 dimer associating with IRF9 
before moving into the nucleus. However, in M1 macrophages, this complex 
synergizes with NFκB to alter transcription, leading to the release of reactive 
nitrogen species. NFκB comes from a signaling pathway activated by a TLR binding 
to its ligand. Multiple ligand-TLR pairs can activate this pathway. MyD88 acts as an 
adapter protein, passing the signal from the receptors to NFκB. Images are based on 
those found in Owen (2020) and Müller et. al. (2018). 
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The rM51R-M strain of VSV has been shown to upregulate components of the type I 
IFN pathway in M2 THP-1 macrophages. The increase in total and phosphorylated STAT1 
over samples infected with wild-type VSV was previously mentioned (Polzin 2020). There is 
also an increase in IFNα signal propagation in rM51R-M virus-infected macrophages (Owen 
2020). It has been further established that VSV is extremely sensitive to the type I IFN 
family of molecules (Bishnoi et. al. 2018). Therefore, we hypothesize that rM51R-M virus 
modulates macrophages to a more inflammatory phenotype via the type I IFN pathway. 
In order to determine the role of the type I IFN pathway in macrophage 
repolarization, we have attempted to chemically inhibit STAT1 phosphorylation/activation 
with fludarabine. Fludarabine is a chemical analog of the antiviral agent vidarabine and a 
known inhibitor of STAT1 phosphorylation (Figure 3). The mechanism of action by which 
fludarabine inhibits the accumulation of p-STAT1 is not well characterized. STAT1 has two 
phosphorylation sites, Y710 and S727. A 2014 study of fludarabine activity in melanoma 
samples indicated downregulation of phosphorylation at both sites (Hanafi et. al. 2014). 
However, as the S727 site becomes phosphorylated downstream of the Y710 site, it is 
unclear if fludarabine directly targets the S727 site or if less phosphorylation occurs due to 
upstream downregulation of Y710. Fludarabine is also a chemotherapeutic agent marketed 
under the name Fludara®. It exhibits a cytotoxic effect on B-cell malignancies such as B-cell 
chronic lymphocytic leukemia and mantle cell lymphoma (Baran-Marszak et. al. 2004). In 
addition, 18F-fludarabine, a radioactive conjugate of fludarabine, has been used in lymphoma 
imaging, as it is specifically taken up by cells with high glucose metabolism (Barré et. al. 
2019). Therefore, it is an important substance to study in the context of cancer treatment 




Figure 3. 2D and 3D models of fludarabine. Images retrieved from PubChem. 
 
 
Our research uses THP-1 cells as a model of human macrophages. THP-1 is an 
immortalized human monocytic leukemia cell line that can be matured and polarized into a 
variety of macrophage phenotypes. PMA can be used to differentiate THP-1 monocytes into 
adherent macrophages (Chanput et. al. 2014). Subsequent treatment with the cytokines IL-4 
and IL-13 polarizes these THP-1 macrophages to an M2 phenotype (Locati et. al. 2020). In 
the experiments presented here, THP-1 monocytes were pre-polarized to an M2 phenotype 
before treating the cells with fludarabine and infecting with rM51R-M virus (Figure 4). 
While the virus can repolarize these M2 macrophages to a more M1-like profile, it was 
expected that the fludarabine-treated M2 macrophages would retain their phenotype 
following viral infection. However, prior to an exhaustive characterization of macrophage 
marker expression, the concentration of fludarabine capable of inhibiting the phosphorylation 
of STAT1 under these assay conditions had to be determined. Therefore, a titration 
experiment was performed to determine the minimum concentration of fludarabine at which 
p-STAT1 accumulation would be inhibited to levels comparable to uninfected and untreated 
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Figure 4. Experimental workflow. THP-1 monocytes were matured and polarized to 
M2 macrophages using PMA, IL-4, and IL-13, exposed to fludarabine, and then 
infected with rM51R-M virus. Cell lysates were then collected and proteins detected 





Methods and Materials 
 
Cells and Virus 
 
THP-1 monocytic leukemia cells were propagated in RPMI media (Corning, 10-040-CV) 
supplemented with 10% fetal bovine serum (R&D Systems, S11150) and 0.05 mM 2-
mercaptoethanol (MP Biomedicals, 190242) between 2 x 105 and 1 x 106 cells/ml. The 
rM51R-M strain of VSV was a gift from Dr. Douglas Lyles of the Wake Forest University 
School of Medicine (Winston-Salem, NC) and has been previously described (Whitlow et al. 
2006). Viral stocks were grown in BHK fibroblasts for 24 hours, spun down, and collected 
into cryovials, then stored at -80°C (Kopecky et al., 2001). Virus was thawed on ice, then 
added to M2-polarized THP-1 macrophages at a MOI of 1 or 10 pfu/cell for a 24-hour 
infection period.  
 
M2 Macrophage Polarization 
 
THP-1 cells were transferred to a 6-well plate at a concentration of 1.4 x 106 cells/well. Here 
they were subsequently polarized to an adherent, M2 macrophage phenotype through a step-
wise 24-hour incubation in THP-1 media containing 25nM PMA followed by a 48-hour 
incubation in THP-1 media containing 25nM PMA, 20ng/mL IL-4, and 20ng/mL IL-13. 
Stocks of PMA (Sigma-Aldrich, P1585) were made as 25μM solutions in DMSO. Stocks of 
IL-4 (Bio-Legend, 574002) and IL-13 (Bio-Legend, 571102) were made as 20μg/mL 
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solutions in 0.05% BSA/PBS. All stock solutions were kept at -80˚C in small volume 




Pre-polarized M2 macrophages were treated with fludarabine (Selleckchem, S1491) at 50, 
100, or 150 μM for 1 hour prior to infection with rM51R-M virus for 24 hours as described 




Following experimental manipulations, the cells were washed twice with ice-cold PBS before 
being scraped into 100 µl of ice-cold RIPA buffer. The RIPA buffer consisted of 50 mM 
Tris-HCl (pH 8.0), 150mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and  
1 μg/mL aprotinin (Fisher Scientific, ICN19455910). The samples were centrifuged at 
16,000xg for 20 min, the pellets discarded, and the supernatants analyzed for protein content 
using a PierceTM BCA Protein Assay Kit (Thermo Scientific, 23225) according to 
manufacturer’s instructions against a series of BSA standards. Cell lysates were incubated at 









For immunoblot analysis, 20μg of lysate protein was loaded onto a 10% polyacrylamide gel, 
separated by SDS-PAGE, and then transferred to a 0.45μm nitrocellulose membrane (Bio-
Rad, 1620115) at 100V for 1 hour. After blocking in 5% milk/TBS-T for 1 hour, membranes 
were washed 3 times at 5 minutes each in TBS-T. Membranes were then incubated overnight 
at 4°C with primary antibody to p-STAT1 (Y701) (Cell Signaling, 9167S) at 1:1000 in 5% 
BSA/TBS-T. Membranes were washed as previously described before incubation with a 
peroxidase-conjugated secondary antibody (GE Healthcare, NA9340V) at 1:2000 in 5% dry 
milk/TBS-T for 1 hour at room temperature. Proteins were visualized using SuperSignalTM 
West Dura Extended Duration Substrate (ThermoFisher Scientific, 34075) or SuperSignalTM 
West Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific, 34080) and Image 
Lab software (Bio-Rad). Image Lab was used to perform the densitometry analysis. This was 






The rM51M-R strain of VSV upregulates the M1 macrophage markers p-STAT1, 
CD80, and TNF-α in a pre-polarized M2 macrophage population (Polzin 2020). The virus 
also reduces secretion of IL-10, a cytokine associated with M2 macrophages (McCanless 
2019). It is suspected that this virus is shifting the macrophages towards a tumor-fighting M1 
phenotype, but the mechanism is not fully appreciated. There are similarities between the 
antiviral type I IFN pathway and the signaling pathways involved in M1 polarization (Figure 
2). Both increase the phosphorylation-dependent activation of the transcription factor 
STAT1. Fludarabine is a small molecule inhibitor of STAT1 phosphorylation/activation. 
Here it was hypothesized that fludarabine would block the repolarization of M2 macrophages 
if the type I IFN pathway was responsible for this phenomenon. This experiment sought to 
determine a fludarabine concentration capable of inhibiting STAT1 phosphorylation under 
the assay conditions being employed. 
 M2 polarized THP-1 macrophages were pre-treated with fludarabine, then infected 
with rM51R-M virus at an MOI of 1 or 10 pfu/cell for 24 hours, after which lysates were 
analyzed for the expression of p-STAT1 (see Figure 4). Mock-infected M2 macrophages 
were also examined as a negative control. Mock-infected M2 THP-1 macrophages exhibited 
low levels of p-STAT1 (Figure 5A). While the band was not visible to the naked eye, 
densitometry analysis returned some p-STAT1 signal, which is likely caused by background 
noise (Figure 5B). This was in contrast to those macrophages subjected to infection with the 
rM51R-M virus, which displayed increases in p-STAT1 levels (Figure 5). These data 
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therefore reaffirm former studies that have shown an increase in STAT1 phosphorylation 
following infection with the mutant virus (Polzin 2020).  
The effect of fludarabine on p-STAT1 levels was as hypothesized with reductions in 
STAT1 phosphorylation (Figure 5A). At an MOI of 1 pfu/cell, STAT1 phosphorylation was 
reduced to between 23% (50 µM fludarabine) and 16 % (100 and 150 µM fludarabine) of the 
levels present without the drug (Figure 5B). This was comparable to the results at an MOI of 
10 pfu/cell, which reduced the levels of p-STAT1 to 32% (50 µM fludarabine) or 16% (100 
µM fludarabine) of the levels present without the drug (Figure 5B). Fludarabine at a 
concentration of 150µM reduced STAT1 phosphorylation to a level comparable to 
background signaling (Figure 5).  
As well as effectively inhibiting p-STAT1, none of the concentrations tested had a 
noticeable effect on the viability of THP-1 cells. Cells were visualized prior to lysate 
collection, and there were no notable signs of cell death, such as floating cells and lower 
plate density. In addition, a protein assay performed on a similar experiment yielded no large 
differences in total protein concentration between rM51R-M-infected THP-1 cells treated 
with fludarabine and those not treated with fludarabine. In this experiment, lysates from 
fludarabine-treated samples had total protein concentrations between 606.4 μg/mL and 665.1 
μg/mL. Lysates from samples with no fludarabine had total protein concentrations between 
624.7 μg/mL and 719.7 μg/mL. Although the total protein concentration is lower in the 
fludarabine-treated samples, there was not enough of a difference to discourage use of 
fludarabine at this concentration. Collectively, these data indicate that 100µM fludarabine 
may be sufficient for future studies where STAT1 inhibition will be tested for its ability to 






Figure 5. Fludarabine inhibits p-STAT1 accumulation in M2 THP-1 macrophages 
following infection with rM51R-M virus. Panel A: THP-1 monocytes were pre-
differentiated into macrophages and polarized to an M2 phenotype. Cells were then 
treated with fludarabine at 0, 50, 100, or 150 µM for one hour prior to a 24-hour 
infection with rM51R-M virus (MOI of 1 or 10 pfu/cell) (see Figure 4). Mock 
indicates no drug treatment and no virus infection. Total cell lysates were subjected 
to immunoblot analysis by probing with a p-STAT1 antibody. Panel B: The 
immunoblot data in Figure 5A was subjected to densitometry analysis in order to 







Previous experiments in our lab have shown that a mutant strain of the oncolytic 
vesicular stomatitis virus, rM51R-M, can reduce M2 markers and activate M1-polarizing 
STAT1 signaling in a THP-1 macrophage population (Polzin 2020). The overarching goal of 
this project was to determine the effects of p-STAT1 inhibition on this re-education of M2 
macrophages. To that end, fludarabine at a concentration ranging from 50 to 150 μM was 
tested for inhibition of STAT1 phosphorylation. Effectiveness of inhibition was determined 
by comparison to M2-polarized macrophages that were not subjected to inhibition with 
fludarabine or infection with rM51R-M.  Fludarabine exhibited inhibition of STAT1 
phosphorylation at all concentrations tested, indicating that this inhibitor is active under the 
conditions of our assay.  
 This experiment used MOIs of 1 and 10 to represent both asynchronous and 
synchronous infections with rM51R-M virus. An MOI of 1 pfu/cell resembles a natural 
infection where the virus will infect and replicate in some cells before spreading to others. 
This will evoke a systematic antiviral response meant to arrest the progression of a natural 
infection. An MOI of 10 pfu/cell models a synchronous infection, in which nearly every cell 
in a system is infected during the introduction of the virus. This allows for the study of the 
antiviral response of individual cells, as viral spread between cells will be limited (Owen 
2020). The extent of the infection, natural (MOI of 1) or synchronous (MOI of 10), elicited 
increasing effects on STAT1 phosphorylation, which was over 2-fold higher under the higher 
viral load (Figure 5). Similarly, the extent of inhibition by fludarabine also depended on the 
multiplicity of infection—the more virus used in the assay, the more fludarabine was needed 
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for full inhibition. In a compromise between maximum effectiveness of the drug with 
presumed limited cytotoxicity, 100 μM is currently considered the ideal fludarabine 
concentration for further experimentation. Although 150 μM fludarabine exhibited slightly 
more inhibition of STAT1 phosphorylation, 100 μM was sufficient to bring levels of p-
STAT1 down to a level comparable to uninfected M2 macrophages at both MOIs. Using this 
lower, but still effective, concentration of fludarabine will also allow for more efficient use of 
this resource.  
STAT1 is not the only marker that can be used to validate the role of type I interferon 
signaling in the repolarization of M2 macrophages in response to VSV infection. Others 
include cell surface markers like HLA-DR, CD11c, and CD86 for M1 macrophages, and 
CD163, CD204, and CD206 for M2 macrophages. The presence of these markers can be 
determined by flow cytometry. This single-cell analytical method will more clearly indicate 
whether individual macrophages are fully or partially displaying macrophage identity 
markers, which cannot be seen in a measure of aggregate protein by immunoblot analysis.  
The molecules secreted by macrophages are also potential targets for macrophage 
identification. M1 macrophages secrete the pro-inflammatory cytokines IL-6, IL-12, and IL-
23, while M2 macrophages secrete IL-10, PD-L1, and TGF-β (Jayasingam et. al. 2020). 
These molecules can be quantified using an ELISA assay. The markers of macrophage 
identity previously used in our lab include p-STAT1, CD204, IL-6, TNF-α, and IL-10. 
Therefore, these are the markers that will receive most of our attention to facilitate 
comparisons to previous work. Marker expression will be compared to that of untreated M1 
or M2 macrophages to give an indication of the identity of macrophage populations exposed 
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to the virus and fludarabine. This step of the project is already in progress, as the initial 
experimental steps are completed up to the collection of cell lysates. 
In addition to western blotting, ELISAs, and/or flow cytometry, functional assays will 
be used to characterize macrophages. A phagocytosis assay for THP-1 macrophages is 
currently in development in our lab. Preliminary data suggests that M2 THP-1 macrophages 
exhibit a ~10-fold higher phagocytic index than M1 THP-1 macrophages based on the uptake 
of fluorescently-labeled E.coli particles. Moreover, the rM51R-M mutant of VSV reduced 
phagocytosis in M2 macrophages by 50% (Simmons, Seals, and Ahmed, personal 
communications). Experiments to test fludarabine’s impact on these results are being 
planned. As phagocytosis is a trademark behavior of macrophages, this assay will allow 
further differentiation of macrophage identity based on functional activity (Locati et. al. 
2020).  
The importance of such an extensive examination of macrophage markers/activity is 
due to the lack of full phenotype characterization of macrophages modulated by rM51R-M 
virus.  Infection with rM51R-M virus has been shown to increase expression of the M1 
markers p-STAT1, CD80, and TNF-α and reduce expression of the M2 marker IL-10 in M2 
THP-1 macrophages (Polzin 2020, McCanless 2019). However, no change was observed in 
the M2 macrophage marker CD204 upon infection with rM5IR-M virus (Polzin 2020). 
Macrophages appear to be moving away from the immunosuppressive M2 subtype as a result 
of rM51R-M viral infection, but they do not completely shed canonical markers of this 
subtype. It is possible that infected macrophages assume an intermediate phenotype between 
M1 and M2. By performing a full characterization of macrophage markers in our samples, 
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we will be able to more accurately describe the population of macrophages emerging post-
infection.  
As there are multiple components in the type I IFN pathway, there are multiple ways 
to validate its role in the repolarization of M2 macrophages by rM51R-M virus. One such 
experiment might consist of IFNα and IFNβ inhibition. This will be done using a human type 
I interferon neutralizing antibody mixture (Fisher Scientific 50-153-8053 [PBL Assay 
Science]). The mixture includes antibodies directed against the human type I interferon 
receptor as well as several of its ligands, including IFNα and IFNβ themselves. We expect 
that this reagent will have similar downstream effects as fludarabine. Importantly, inhibiting 
another molecule in the IFNα/β pathway will either reaffirm the findings from the 
fludarabine experiment or indicate an alternative mode of macrophage repolarization if the 
results are not comparable.  
If type I interferon signaling antagonists fail to block universal changes in 
macrophage phenotype or lead to intermediate phenotypes, then it could indicate that this 
pathway is not solely responsible for macrophage re-education as a result of  
rM51R-M viral infection. The reason for this would need additional research to determine. It 
could be that the type I IFN pathway does not play a role at all in macrophage identity shift. 
It is also possible that the type I IFN pathway plays a role, but that other pathways 
compensate for its loss when inhibition occurs. To this end, additional experiments will be 
performed with the purpose of determining the extent of activation in other pathways under 
our experimental conditions, such as activation of TLR and NFκB.  
The TLR pathway is of interest for future experimentation. Wild-type VSV has been 
shown to stimulate a subset of dendritic cells through TLR7 and MyD88 (Ahmed et. al. 
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2009). However, stimulation of other dendritic cell subsets by rM51R-M virus occurred in a 
way that was largely independent of TLR7 and MyD88. Yet, rM51R-M virus upregulated 
NFκ-B in dendritic cells over mock-infected samples (Ahmed et. al. 2009). Although 
dendritic cells are an immune population distinct from macrophages, it is possible that 
rM51R-M virus has similar effects on the pathways these populations share. As such, it is 
possible that r-M51R-M virus creates synergy between STAT1/2 and NFκ-B signaling in 
macrophages through a pathway different than the one outlined in Figure 2. While beyond 
the scope of this study, the question of whether r-M51R-M virus activates the TLR/MyD88 
pathway in macrophages is a possible avenue for further experimentation. 
Our study is hardly the first one to examine the effects of oncolytic viruses on 
macrophage identity. Passaro found that the oncolytic adenovirus dl922-947 prevents the 
infiltration of M2 macrophages into anaplastic thyroid carcinoma tumors (Passaro et. al. 
2016). It does this by reducing the production of CCL2 by cancer cells. In vitro, this 
reduction lowered monocyte chemotaxis. The virus also shifted macrophages towards an M1 
phenotype in vivo, as seen by increased Nos2 expression (Passaro et. al. 2016). Another study 
showed that an oncolytic virus increased inflammatory macrophage activity (Tan et. al. 
2016). Attenuated paramyxoviruses (the class of virus that measles and mumps belong to) 
were found to be more effective at breast cancer tumor clearance when virally-infected 
macrophages were present. This could be attributable to the increase in M1 macrophage 
markers seen in virus-infected samples. M1-associated tumoricidal mediators were also 
found to be responsible for reduced tumor viability in vitro (Tan et. al. 2016). When 
combined with the studies published by Polzin (2020) and extended as part of this thesis, it 
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seems clear that macrophage repolarization can be a novel therapeutic benefit of oncolytic 
virotherapies. 
This research also has implications for the use of fludarabine in the clinic. As stated 
prior, fludarabine is administered as a chemotherapy under the name Fludara®, and is also 
utilized in cancer imaging. If fludarabine is found to inhibit the shift of macrophages to a 
phenotype more beneficial for the patient, it would raise questions about the use of 
fludarabine when patients are receiving an oncolytic virotherapy. 
Here we have validated the use of fludarabine as an inhibitor of STAT1 signaling 
induced by infection of M2 THP-1 macrophages with a mutant strain of VSV called  
rM51R-M. Further research will substantiate the extent to which such signaling yields 
repolarization of macrophages to an anti-tumor M1 population, but if so, oncolytic viruses 
capable of re-training the immune system to clear cancerous cells could become another tool 
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